Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

disease control rate

the proportion of patients achieved CR, PR, or stable disease \[SD\]

Time frame: up to 18 weeks

duration of response

time interval from the first day of documented response to progressive disease \[PD\] or death from any cause

Time frame: From date of documented response until the date of progressive disease [PD] or death, whichever came first, assessed up to 12 months

progression-free survival

time interval from the enrolled date to the documented PD or death from any cause or censored at the last follow-up

Time frame: From date of the enrollment until the date of the documented PD or death, whichever came first, assessed up to 12 months

overall survival

time interval from the enrolled date to death from any cause or last follow-up

Time frame: From date of the enrollment until the date of the documented death, assessed up to 72 months

adverse events

treatment-related adverse events graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

Time frame: up to 18 weeks